Canadian clinical trial registry

Search results

Information is also accessible through the patient and families tab. Family friendly summaries are created and reviewed by our advocacy partners. The information is updated to the best of our knowledge but might not reflect the latest information. Note that most studies are only available at a limited number of sites, please click on ‘further information’ for details. Studies, particularly early phase trials, may also temporarily close to enrolment or not have slots available for all treatment groups. In all cases, study teams at individual C17 centres will have the most up-to-date information.

88 results found

Title
Status

 

PBTC-049 - A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations

Open

PBTC-049 - A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations

Go to Health Care Provider version

DiagnosisRecurrent or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent or Refractory Malignant Glioma, Recurrent or Refractory Medulloblastoma, Recurrent or Refractory Primary Central Nervous System NeoplasmStudy StatusOpen
PhaseI
Age6 Years to 21 YearsRandomisationN/A
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationDrug: Savolitinib (Oral) Other Names: AZD 6094 AZD6094 HMPL-504 Volitinib
Last Posted Update2024-02-13
ClinicalTrials.gov #NCT03598244
International Sponsor
National Cancer Institute (NCI)
Principal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Vijay Ramaswamy
Centres
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

 

 

Study Description

PBTC-049 tests a drug called savolitinib to see how well it works in children with these tumors. This drug has not been studied in children. The hope is that this drug may be a more effective treatment for these types of brain tumors in children.

Therefore, the primary goals of the study are to:

  • Determine which dose of savolitinib is safe for children
  • Learn what effects (good or bad) may occur when patients take savolitinib
  • Learn how the body processes savolitinib

(via: PBTC-049_Summary for patients & families_05-18-2020.pdf)

Inclusion Criteria
  • Patients with confirmed medulloblastoma, high-grade glioma, DIPG brain tumors, and other brain tumor types with a specific genetic marker, which continue to grow or have come back after the prior treatment may be eligible to participate.
  • Patients must be between 5-21 years of age.
  • Patients must have recovered from toxicities of all prior chemotherapy, immunotherapy, radiotherapy or any other treatment modality prior to entering this study.
  • Pregnant women and nursing mothers are excluded from this study
  • Patients or a parent/guardian must understand and sign a written consent form to participate
  • Patients and/or their families must agree to the study visit requirements outlined in the consent form

(via: PBTC-049_Summary for patients & families_05-18-2020.pdf)

Other inclusion criteria may apply and will be discussed with you by the study team.

PBTC-060 - A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Open

PBTC-060 - A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Go to Health Care Provider version

DiagnosisMedulloblastoma, Glioblastoma, Anaplastic Astrocytoma, Oligodendroglioma, Ependymoma, Diffuse Intrinsic Pontine GliomaStudy StatusOpen
PhaseI
Age1 Year to 21 YearsRandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationBiological: SurVaxM (injection) 500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients < 30 kg, and 100 mcg for patients ≥ 30 kg.
Last Posted Update2024-02-13
ClinicalTrials.gov #NCT04978727
International Sponsor
Pediatric Brain Tumor Consortium
Principal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Vijay Ramaswamy
Centres
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

 

 

Study Description

Patients on this study will receive 4 doses of a vaccine called SurVaxM. While vaccines are usually thought of as ways to prevent diseases, vaccines can also be used to treat cancer. SurVaxM is designed to tell the body's immune system to look for tumor cells that express a protein called survivin and destroy them. If the body's immune system knows to destroy cells that express survivin, it may help to control tumor growth and recurrence.

 

Inclusion Criteria
  • Participant must have one of the following tumors that has progressed or come back: 
    • Medulloblastoma
    • Glioblastoma multiforme 
    • Anaplastic astrocytoma
    • High-grade astrocytoma, NOS
    • Anaplastic oligodendroglioma
    • Anaplastic ependymoma
    • Ependymoma 
    • Diffuse Intrinsic Pontine Gliomas (DIPG)
  • Participant must be ≥ 1 year of age and ≤ 21 years of age at the time of screening.
  • Participant or parent/guardian must be willing to sign a consent form and complete the study related assessments.
  • Participants must have recovered from all previous cancer therapies. 
  • Must be up and about for around 60% of the patient's waking hours
  • Participants must meet all the blood work requirements 
  • You cannot be pregnant or become pregnant on this study. If you are able to have children, you must use an acceptable form of birth control. Abstinence is included. 

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team.

PED-CITN-03 - Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined With Dinutuximab in Children and Young Adults With Relapsed and Refractory Neuroblastoma or Relapsed Osteosarcoma

Closed to enrollment

PED-CITN-03 - Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined With Dinutuximab in Children and Young Adults With Relapsed and Refractory Neuroblastoma or Relapsed Osteosarcoma

Go to Health Care Provider version

DiagnosisNeuroblastoma, OsteosarcomaStudy StatusClosed to enrollment
PhaseI
AgeChild, Adult - (up to 35 Years)RandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationDinutuximab: intravenous Magrolimab: intravenous
Last Posted Update2024-02-13
ClinicalTrials.gov #NCT04751383
International Sponsor
COG Pediatric Early Phase Clinical Trials Network (PEP-CTN)
Principal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Daniel A. Morgenstern
BC Children's Hospital - Dr. Rebecca Deyell
Centres
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

Medical contact
Rebecca Deyell

 

Social worker/patient navigator contact
Ilana Katz 

 

Clinical research contact
Hem/Onc/BMT Clinical Trials Unit

 

 

 

Study Description

The purpose of this study is to determine the best dose, benefits and/or side effects of 2 drugs (magrolimab and dinutuximab) when given in combination to treat neuroblastoma that has come back (relapsed) or does not respond to treatment (refractory), or osteosarcoma that has come back (relapsed). These drugs (magrolimab and dinutuximab) interfere with the ability of cancer cells to grow and spread, using them in treatment may stop or shrink cancer growth in cases of neuroblastoma and osteosarcoma.

An additional aim of this study is determining the safety of these drugs (magrolimab and dinutuximab) when given after surgery to remove tumors from the lungs.

Inclusion Criteria
  • Age between 1 and 35 years
  • Patients must have:
    • neuroblastoma that has come back (relapsed) or does not respond to treatment (refractory) or
    • osteosarcoma that has come back (relapsed)
  • Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

ADVL1823 - Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias

Closed to enrollment

ADVL1823 - Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias

Go to Health Care Provider version

Diagnosis Infantile fibrosarcoma with TRK fusion, any solid tumour with TRK fusion, any brain tumour with TRK fusion (except high grade glioma), any relapsed acute leukemia with TRK fusionStudy StatusClosed to enrollment
PhaseII
AgeChild, Adult - (up to 30 Years)RandomisationNO
Line of treatmentFirst line treatment, Disease relapse or progression
Routes of Treatment AdministrationOral
Last Posted Update2024-02-12
ClinicalTrials.gov #NCT03834961
International Sponsor
Children's Oncology Group
Principal Investigators for Canadian Sites
IWK Health Centre - Dr. Craig Erker
CHU Sainte-Justine - Dr. Yvan Samson
Montreal Children's Hospital – Dr. Sharon Abish
Centres
Medical contact
Dr. Craig Erker
Dr. Conrad Fernandez 
Dr. Ketan Kulkarni 
 
Social worker/patient navigator contact
Rhonda Brophy
 
Clinical research contact
Tina Bocking
 
Medical contact
Dr. Henrique Bittencourt
Dr. Monia Marzouki
Dr. Sebastien Perreault (neuro-onc)
 
Social worker/patient navigator contact
Marie-Claude Charrette
 
Clinical research contact
Marie Saint-Jacques
 
Medical contact
Clinical Research Unit
 
Social worker/patient navigator contact
Clinical Research Unit
 
Clinical research contact
Stephanie Badour
 

 

 

Study Description

This clinical trial studies the side effects and how well larotrectinib (a medication taken by mouth) works in treating patients with

  • solid tumors and brain tumours with a specific gene change called a "TRK fusion", previously untreated
  • acute leukemia that has come back, and has a specific gene change called a "TRK fusion".

Larotrectinib may stop the growth of cancer cells with TRK fusions by blocking the TRK enzymes needed for cell growth.

Inclusion Criteria
  • Age up to 30 years
  • Patients must fit into one of the 3 groups
    • Group A: diagnosis of infantile fibrosarcoma with a specific gene change called a "TRK fusion". The patient will have received no prior anti-cancer therapy, including radiotherapy, other than surgical resection (operation to remove the tumour)
    • Group B: diagnosis of any solid tumor including brain tumours (except high grade gliomas), with a specific gene change called a "TRK fusion". The patient will have received no prior anti-cancer therapy, including radiotherapy, other than surgical resection (operation to remove the tumour)
    • Group C: diagnosis of acute leukemia that has come back, and has a specific gene change called a "TRK fusion".
  • Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

APAL2020SC - Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Open

APAL2020SC - Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Go to Health Care Provider version

DiagnosisAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome Post Cytotoxic TherapyStudy StatusOpen
PhaseI/II
AgeLess than 22 years of ageRandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationProcedure: Biospecimen Collection Undergo collection of blood and/or bone marrow samples
Last Posted Update2024-02-12
ClinicalTrials.gov #NCT04726241
International Sponsor
LLS PedAL Initiative, LLC
Principal Investigators for Canadian Sites
CHU Quebec - Dr. Bruno Michon
Alberta Children's Hospital - Dr. Victor Lewis
Stollery Children's Hospital - Dr Sarah McKillop
BC Children's Hospital - Dr. Rebecca Deyell
CancerCare Manitoba - Dr. Ashley Chopek
IWK Health Centre - Dr. Craig Erker
London Children's Hospital - Dr. Shayna Zelcer
Children's Hospital Eastern Ontario (CHEO) - Dr. Donna Johnson
The Hospital for Sick Children - Dr. Johann Hitzler
Montreal Children's Hospital - Dr. Stephanie Mourad
CHU Ste. Justine - Dr. Monia Marzouki
Centres
Medical contact
Dr. Henrique Bittencourt
Dr. Monia Marzouki
Dr. Sebastien Perreault (neuro-onc)
 
Social worker/patient navigator contact
Marie-Claude Charrette
 
Clinical research contact
Marie Saint-Jacques
 
Medical contact
Raoul Santiago
 
Social worker/patient navigator contact
Isabelle Audet
 
Clinical research contact
Barbara Desbiens
 

 

Medical contact
Clinical Research Unit
 
Social worker/patient navigator contact
Clinical Research Unit
 
Clinical research contact
Stephanie Badour
 
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

Medical contact
Dr. Donna Johnston
Dr. Lesleigh Abbott
Dr. Doaa Abdel Fattah
 
Social worker/patient navigator contact
Sherley Telisma
 
Clinical research contact
Carol Duchenne
 
Medical contact
Dr. Alexandra Zorzi
Dr. Shayna Zelcer
 
Social worker/patient navigator contact
Cindy Milne Wren
Jessica Mackenzie Harris
 
Clinical research contact
Mariam Mikhail
Medical contact
Dr. Craig Erker
Dr. Conrad Fernandez 
Dr. Ketan Kulkarni 
 
Social worker/patient navigator contact
Rhonda Brophy
 
Clinical research contact
Tina Bocking
 
Medical contact
Dr. Magimairajan Vanan
Social worker/patient navigator contact
Rhéanne Bisson
 
Clinical research contact
Rebekah Hiebert
Megan Ridler
Kathy Hjalmarsson

 

 

Medical contact
Rebecca Deyell

 

Social worker/patient navigator contact
Ilana Katz 

 

Clinical research contact
Hem/Onc/BMT Clinical Trials Unit

 

Medical contact
Dr. Victor Lewis

 

Social worker/patient navigator contact
Wendy Pelletier
Clinical research contact
Debra Rich
Medical contact
Dr. Sarah McKillop
Dr. Sunil Desai

 

 

Social worker/patient navigator contact
Danielle Sikora
 Michelle Woytiuk 
Jaime Hobbs
Clinical research contact
Amanda Perreault

 

 

Study Description

This study will test bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat, which may provide information about the patient's leukemia that is important when deciding how to best treat it and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.

Inclusion Criteria
  • Patient must be less than 22 years old
  • Patient must have a leukemia that has come back or not responded to other treatment
  • Patient and/or their family must sign a written informed consent and agree to the study requirements 

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team

MYTHIC (RP-6306) - Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 in Patients With Advanced Solid Tumors (MYTHIC Study)

Closed

MYTHIC (RP-6306) - Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 in Patients With Advanced Solid Tumors (MYTHIC Study)

Go to Health Care Provider version

DiagnosisAdvanced Solid TumorStudy StatusClosed
PhaseI
Age12 years and olderRandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationRP-6306 (PKMYT1 Inhibitor): Oral
Last Posted Update2024-01-19
ClinicalTrials.gov #NCT04855656
International Sponsor
Repare Therapeutics
Principal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Daniel Morgenstern
Centres
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

 

 

Study Description

(via: https://www.mskcc.org/cancer-care/clinical-trials/21-303)

The purpose of this study is to find the highest dose of the investigational drug RP-6306 that can be used in advanced solid tumors containing certain genetic changes and which have come back or continued to grow despite prior treatment. 

RP-6306 blocks the protein PKMY1, which plays a major role in the survival and growth of cancers with the genetic changes being studied in this clinical trial. RP-6306 is taken orally (by mouth).

Inclusion Criteria

(via: https://www.mskcc.org/cancer-care/clinical-trials/21-303)

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a locally advanced or metastatic solid tumor that has come back or continued to grow despite prior treatment
  • Participants’ tumors must contain a mutation in the FBXW7 or PPP2R1A genes or extra copies of the CCNE1 gene
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours
  • This study is for people age 12 and older

Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.

YmAbs201 - A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Open

YmAbs201 - A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Go to Health Care Provider version

DiagnosisNeuroblastomaStudy StatusOpen
PhaseII
AgeChild, Adult, Older Adult - (1 Year and older)RandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment Administrationnaxitamab (intravenous); GM-CSF (sub-cutaneous)
Last Posted Update2024-01-19
ClinicalTrials.gov #NCT03363373
International Sponsor
Y-mAbs Therapeutics
Principal Investigators for Canadian Sites
The Hospital for Sick Children – Dr. Daniel Morgenstern
Centres
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

 

 

Study Description

This is a study of naxitamab, also known as hu3F8, a humanised antibody targeting GD2 in children and adults diagnosed with high-risk neuroblastoma. GD2 is a marker present at the surface of the neuroblastoma cells; therefore the naxitamab can target the neuroblastoma cells and stimulate the immune system to kill them.

Patients with with primary refractory disease (disease that has never improved with previous treatment), or patients that have had a relapse but incomplete response of the disease in bone and/or bone marrow from salvage treatment will be considered for this study.

Granulocyte-macrophage colony stimulating factor (GM-CSF) will be given along naxitamab.

Inclusion Criteria
  • Diagnosis of high-risk neuroblastoma with disease in bone and/or bone marrow.
  • High-risk neuroblastoma patients with either primary refractory disease or incomplete response to salvage treatment
  • Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

STEP-RB - Phase I Sustained-Release Topotecan Episcleral Plaque (Chemoplaque) for Retinoblastoma

Closed to enrollment

STEP-RB - Phase I Sustained-Release Topotecan Episcleral Plaque (Chemoplaque) for Retinoblastoma

Go to Health Care Provider version

DiagnosisRetinoblastoma Study StatusClosed to enrollment
PhaseI
AgeChild - (up to 17 Years)RandomisationNO
Line of treatmentFirst line treatment, Disease relapse or progression
Routes of Treatment AdministrationTopotecan - administered using an episcleral plaque (chemoplaque), an implant which contains topotecan (drug). The implant is attached to the outside of the eye and delivers topotecan directly into the eye.
Last Posted Update2024-01-09
ClinicalTrials.gov #NCT04428879
International Sponsor
The Hospital for Sick Children
Principal Investigators for Canadian Sites
The Hospital for Sick Children - Daniel Morgenstern
Centres
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

 

 

Study Description

This clinical trial studies the side effects and how well a chemoplaque with topotecan (a medication attached to the outside of the eye) works in treating patients with retinoblastoma. This plaque has to be installed and removed under general anesthesia by the ophthalmology team. It delivers the chemotherapy inside the eye.

Inclusion Criteria
  • Age up to 18 years
  • Retinoblastoma in at least one eye
  • Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team